Vision & Mission
Akcea Therapeutics is a development and commercialization company focused on helping patients living with serious and rare diseases.
Our priority is to bring transformative medicines to patients by driving clinical program execution, understanding patient and physician needs, preparing the market, creating market access, and commercializing our products on a global basis.
We are driven by the knowledge that patients depend on us.
Akcea, a wholly-owned subsidiary of Ionis Pharmaceuticals, was established in early 2015 and based in the Seaport District in Boston, Massachusetts. Akcea has a robust portfolio of development- and registration-stage drugs covering multiple targets and diseases using advanced RNA-targeted antisense therapeutics. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Ionis standards of excellence.